Oxford BioMedica expands licensing deal with Pfizer

Oxford BioMedica Plc, a developer of gene-based medicines and cancer vaccines, has expanded a licensing agreement with Pfizer Inc giving the US multinational non-exclusive rights to its antibody technology for diagnostic use.